brain tissue News
-
Cercare Perfusion Featured on TV4’s Morning News
Last week Tobias Granberg, a Swedish researcher from Karolinska Institutet, appeared on TV4 Nyhetsmorgon together with his colleague Miia Kivipelto to share the results of their research where they investigated the influence of COVID-19 on the brain using, among others, Cercare Perfusion. The research shows changes in brain tissue vasculature in patients with long COVID-19. Continued ...
-
Lumosa One of the Finalists for Clinical Advance of the Year Award in Scrip Awards 2022
We are delighted to announce that Lumosa's LT3001 (odatroltide) has been shortlisted for the "Clinical Advance of the Year Award" at this year's Pharma Intelligence Scrip Awards. This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. Other finalists include Boehringer Ingelheim and Eli Lilly's ...
-
EPA to hold public hearing on air quality standards for carbon monoxide
The U.S. Environmental Protection Agency (EPA) will hold a public hearing Feb. 28 on the agency’s proposal to retain the nation’s air quality standards for carbon monoxide (CO) and to take steps to gather additional data through more focused monitoring. The science shows that the current standards will protect people, especially those susceptible to health problems associated with ...
-
Infuseon Therapeutics Earns FDA Clearance for Novel Central Nervous System Delivery Device
Infuseon Therapeutics’ novel central nervous system deliver device has received FDA 510(k) clearance as a therapeutic delivery device. Infuseon Therapeutics’ Cleveland Multiport CatheterTM (CMC), a multiport convection-enhanced delivery catheter, was designed by neurosurgeon Michael Vogelbaum, MD, PhD, from Cleveland Clinic’s Brain Tumor and NeuroOncology Center and Department ...
-
Arterys Partners With Cercare Medical to Offer Advanced Perfusion Brain CT and MR Imaging Analysis Accelerating Access to Deep, Fast, and Reliable Insights
SAN FRANCISCO, November 29, 2021 (Newswire.com) - Arterys, the world's leading vendor-neutral AI platform, today announced its partnership with Cercare Medical to make their AI-powered imaging solution, Cercare Perfusion, available on the Arterys Platform. Arterys has fully integrated the Cercare Perfusion solution which will be available via its FDA-cleared and CE marked MICA platform to its ...
By Arterys Inc.
-
Current Treatment Options and Research for Glioblastoma
Glioblastoma originates in the brain and typically does not spread to other parts of the body. It is a particularly difficult cancer to treat because tumors often overlap with healthy brain tissue making full surgical removal usually impossible. Treatments such as chemotherapy and radiation may slow the disease’s progression, but there is currently no cure. Glioblastoma Multiforme is the ...
-
Artificial Intelligence Can Help Doctors Diagnose Brain Tumors During Surgery. Here’s How.
A new laser-imaging technology and artificial intelligence are poised to significantly advance what neurosurgeons can do to help patients with brain tumors by potentially improving diagnostic accuracy and cutting testing turnaround time from 30 minutes or more to less than three minutes. A new imaging technique and artificial intelligence (AI) are poised to significantly advance what ...
-
NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology. In test ...
-
Made in Quebec: Illuminating hidden brain cancer cells
It’s a scene that plays out daily in operating rooms around the world: a surgeon removes a malignant brain tumour. But rather than registering the satisfaction of having saved a patient’s life, hanging in the air is an all-too-real statistic; in 99.5% of these operations, unseen cancer cells remain. That hidden cancer will eventually grow and spread, and the operation will have become ...
-
University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
-
University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
-
GammaTile Therapy Delivers Targeted Radiation to Cancer Cells
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor. The current standard of care for patients with ...
-
Synchron receives green light from FDA to begin breakthrough trial of implantable brain computer interface in US
Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the Stentrode™ motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety ...
-
An Overview of Glioblastoma
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. GBM is a Grade IV ...
-
New Preclinical Research Published in Nature Highlights an Active Role by Microbiome-Derived Metabolites in Brain Function and Anxiety-like Behavior
Study adds to growing evidence for how gut microbiome impacts Central Nervous System (CNS) function and behavior in mice Research offers valuable mechanistic insights for understanding the potential role of microbial metabolites in neurodevelopmental disorders Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological ...
-
M Health Fairview University of Minnesota Medical Center Receives First Hyperfine Portable MRI to Grow its Advanced Imaging Systems Offering
Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine”), creator of the first U.S. Food and Drug Administration (“FDA”) cleared portable magnetic resonance imaging (“MRI”)TM device, Swoop®, is proud to announce that M Health Fairview is deploying a Swoop system in the emergency room (ER), intensive care unit (ICU) and post anesthesia environments at M Health Fairview ...
By Hyperfine
-
Woolsey Pharmaceuticals Emerges from Stealth Mode to Announce Patients Enrolled in Two New CNS Studies
NEW YORK, February 18, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced dosing of the first patient with BRAVYL in its FOUND (Fasudil fOr Uncontrolled waNDering) study for Alzheimer’s and Vascular Dementia patients who have wandering behaviors of elopement and/or getting lost. The Company also announced the ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
Discover our top-selling Precellys kits!
For many years, scientists all around the globe have been using Precellys lysing and grinding kits, as they have been proven efficient and safe in a broad range of research areas including microbiology, pharmacology, cancer, forensic medicine, the environment, and even agronomy. Here below, discover our top three bestselling kits and find the perfect solution for your sample prep! ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you